Merck (MRK) Announces Positive Topline Results from PNEU-DIRECTION (V114-027) and PNEU-PLAN (V114-024) Phase 3 Pediatric Studies for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Va
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. Merck (NYSE: